Co-Authors
This is a "connection" page, showing publications co-authored by ANIL K SOOD and GABRIEL LOPEZ.
Connection Strength
8.130
-
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010 Dec; 9(12):3186-99.
Score: 0.373
-
Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010 Aug 09; 18(2):185-97.
Score: 0.369
-
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest. 2010 May; 120(5):1515-23.
Score: 0.361
-
Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res. 2007 Nov 01; 67(21):10389-96.
Score: 0.305
-
Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther. 2006 Dec; 5(12):1708-13.
Score: 0.288
-
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005 Aug 01; 65(15):6910-8.
Score: 0.261
-
Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. Oncotarget. 2015 Feb 28; 6(6):4266-73.
Score: 0.127
-
Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun. 2014 Oct 03; 5:5092.
Score: 0.123
-
Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol Cancer Ther. 2014 Dec; 13(12):2876-85.
Score: 0.123
-
Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2014 Nov; 13(11):2583-94.
Score: 0.122
-
Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014 Jul 14; 26(1):77-91.
Score: 0.121
-
Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer. Mol Cancer Ther. 2014 Jul; 13(7):1750-7.
Score: 0.119
-
Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93.
Score: 0.119
-
Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep. 2014 Apr 24; 7(2):488-500.
Score: 0.119
-
2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun. 2014 Mar 12; 5:3459.
Score: 0.118
-
Autocrine effects of tumor-derived complement. Cell Rep. 2014 Mar 27; 6(6):1085-1095.
Score: 0.118
-
Monocyte subpopulations in angiogenesis. Cancer Res. 2014 Mar 01; 74(5):1287-93.
Score: 0.118
-
Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014 Feb; 66:110-6.
Score: 0.117
-
Nanotechnology in cancer therapy. J Drug Target. 2013 Dec; 21(10):904-13.
Score: 0.115
-
Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology. 2013 Jul; 58(1):182-91.
Score: 0.112
-
ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2013 May; 123(5):2119-30.
Score: 0.111
-
Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res. 2013 Apr 01; 19(7):1806-15.
Score: 0.110
-
Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4:2427.
Score: 0.109
-
Src activation by ?-adrenoreceptors is a key switch for tumour metastasis. Nat Commun. 2013; 4:1403.
Score: 0.109
-
Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol. 2013 Mar; 128(3):506-11.
Score: 0.108
-
Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer. Clin Cancer Res. 2013 Jan 01; 19(1):170-82.
Score: 0.108
-
Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Lett. 2013 Apr 28; 330(2):123-9.
Score: 0.105
-
FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. 2012 Oct; 33(10):1843-53.
Score: 0.104
-
Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012 Feb 16; 366(7):610-8.
Score: 0.103
-
Up-regulation of Cav?3 subunit in primary sensory neurons increases voltage-activated Ca2+ channel activity and nociceptive input in neuropathic pain. J Biol Chem. 2012 Feb 17; 287(8):6002-13.
Score: 0.101
-
Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst. 2011 Nov 02; 103(21):1596-612.
Score: 0.100
-
Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res. 2011 Sep 15; 71(18):6030-9.
Score: 0.099
-
Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res. 2011 Sep 01; 17(17):5674-85.
Score: 0.098
-
MicroRNA therapeutics: principles, expectations, and challenges. Chin J Cancer. 2011 Jun; 30(6):368-70.
Score: 0.098
-
Chitosan hydrogel for localized gene silencing. Cancer Biol Ther. 2011 May 01; 11(9):839-45.
Score: 0.097
-
Hyperthermia induced by magnetic nanoparticles improves the effectiveness of the anticancer drug cis-diamminedichloroplatinum. J Nanosci Nanotechnol. 2011 May; 11(5):4153-7.
Score: 0.097
-
Dopamine blocks stress-mediated ovarian carcinoma growth. Clin Cancer Res. 2011 Jun 01; 17(11):3649-59.
Score: 0.097
-
Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer. Clin Cancer Res. 2011 Jun 01; 17(11):3716-26.
Score: 0.097
-
Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res. 2011 Apr 01; 17(7):1713-21.
Score: 0.096
-
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2011 Jan; 11(1):59-67.
Score: 0.095
-
Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem. 2010 Nov 12; 285(46):35462-70.
Score: 0.093
-
Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther. 2010 Aug; 9(8):2377-88.
Score: 0.092
-
Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res. 2010 Aug 01; 16(15):3910-22.
Score: 0.091
-
Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med. 2010 Jan; 267(1):44-53.
Score: 0.089
-
c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res. 2010 Jan 01; 16(1):184-94.
Score: 0.088
-
The ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment. PLoS One. 2009 Oct 22; 4(10):e7502.
Score: 0.087
-
Novel strategies for reversing platinum resistance. Drug Resist Updat. 2009 Dec; 12(6):148-52.
Score: 0.087
-
Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther. 2009 Jun; 8(11):1027-34.
Score: 0.085
-
Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 01; 15(11):3770-80.
Score: 0.085
-
Liposomal siRNA for ovarian cancer. Methods Mol Biol. 2009; 555:29-42.
Score: 0.083
-
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008 Dec 18; 359(25):2641-50.
Score: 0.082
-
Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res. 2008 Dec 15; 14(24):8143-51.
Score: 0.082
-
Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 2008 Jul 15; 68(14):5849-58.
Score: 0.080
-
Strategies for in vivo siRNA delivery in cancer. Mini Rev Med Chem. 2008 Mar; 8(3):248-55.
Score: 0.078
-
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst. 2008 Mar 05; 100(5):359-72.
Score: 0.078
-
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res. 2007 Nov 15; 67(22):10976-83.
Score: 0.076
-
Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem. 2007 Oct 12; 282(41):29919-26.
Score: 0.075
-
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res. 2006 Aug 15; 12(16):4916-24.
Score: 0.070
-
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006 Aug; 12(8):939-44.
Score: 0.070
-
Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell. 2014 Dec 08; 26(6):863-879.
Score: 0.031
-
miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun. 2014 Dec 05; 5:5671.
Score: 0.031
-
MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol. 2015 Jan; 235(1):25-36.
Score: 0.031
-
miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature. 2014 Aug 28; 512(7515):431-5.
Score: 0.030
-
Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol. 2014 May 05; 10:728.
Score: 0.030
-
EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis. 2014 May; 35(5):1100-9.
Score: 0.029
-
Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS One. 2013; 8(11):e79167.
Score: 0.029
-
Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013 Nov; 3(11):1302-15.
Score: 0.029
-
A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 2013 Aug 12; 24(2):229-41.
Score: 0.028
-
Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proc Natl Acad Sci U S A. 2013 Jul 09; 110(28):E2572-81.
Score: 0.028
-
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013 Feb 11; 23(2):186-99.
Score: 0.027
-
Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res. 2013 Feb 15; 19(4):809-20.
Score: 0.027
-
Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res. 2012 Dec 15; 18(24):6648-57.
Score: 0.027
-
N-methyl-D-aspartate receptor- and calpain-mediated proteolytic cleavage of K+-Cl- cotransporter-2 impairs spinal chloride homeostasis in neuropathic pain. J Biol Chem. 2012 Sep 28; 287(40):33853-64.
Score: 0.026
-
Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One. 2012; 7(7):e41171.
Score: 0.026
-
Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res. 2012 Jul 19; 14(4):R108.
Score: 0.026
-
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8(4):445-544.
Score: 0.026
-
Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Hum Pathol. 2012 Oct; 43(10):1638-44.
Score: 0.026
-
Neuropilin-2 mediated ?-catenin signaling and survival in human gastro-intestinal cancer cell lines. PLoS One. 2011; 6(10):e23208.
Score: 0.025
-
Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology. 2011 Nov; 141(5):1728-37.
Score: 0.025
-
Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One. 2011; 6(7):e21121.
Score: 0.025
-
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011 Jun 07; 8(8):467-77.
Score: 0.024
-
Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One. 2011 Mar 21; 6(3):e17918.
Score: 0.024
-
Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res. 2011 Apr 15; 17(8):2250-9.
Score: 0.024
-
Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer. 2010 Dec; 17(4):1021-33.
Score: 0.023
-
SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell. 2010 Aug 09; 18(2):109-21.
Score: 0.023
-
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010 May 01; 70(9):3687-96.
Score: 0.023
-
Role of M2, M3, and M4 muscarinic receptor subtypes in the spinal cholinergic control of nociception revealed using siRNA in rats. J Neurochem. 2009 Nov; 111(4):1000-10.
Score: 0.022
-
Relaxin/RXFP1 signaling in prostate cancer progression. Ann N Y Acad Sci. 2009 Apr; 1160:379-80.
Score: 0.021
-
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res. 2008 Nov 01; 68(21):9078-86.
Score: 0.020
-
Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene. 2008 Dec 04; 27(57):7192-200.
Score: 0.020
-
The previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression. Cancer Res. 2008 Jun 01; 68(11):4321-30.
Score: 0.020
-
Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res. 2008 Apr 15; 14(8):2476-83.
Score: 0.020
-
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst. 2008 Jan 16; 100(2):109-20.
Score: 0.019
-
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest. 2007 Dec; 117(12):4044-54.
Score: 0.019